139 related articles for article (PubMed ID: 33753155)
1. Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
Rühle A; Grosu AL; Wiedenmann N; Stoian R; Haehl E; Zamboglou C; Baltas D; Werner M; Kayser G; Nicolay NH
Radiother Oncol; 2021 Jun; 159():75-81. PubMed ID: 33753155
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial.
Nicolay NH; Rühle A; Wiedenmann N; Niedermann G; Mix M; Weber WA; Baltas D; Werner M; Kayser G; Grosu AL
J Nucl Med; 2021 Apr; 62(4):471-478. PubMed ID: 32859699
[TBL] [Abstract][Full Text] [Related]
4. Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.
Nicolay NH; Wiedenmann N; Mix M; Weber WA; Werner M; Grosu AL; Kayser G
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1046-1055. PubMed ID: 31811344
[TBL] [Abstract][Full Text] [Related]
5. FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Bandurska-Luque A; Löck S; Haase R; Richter C; Zöphel K; Abolmaali N; Seidlitz A; Appold S; Krause M; Steinbach J; Kotzerke J; Zips D; Baumann M; Troost EGC
Radiother Oncol; 2019 Jan; 130():97-103. PubMed ID: 30293643
[TBL] [Abstract][Full Text] [Related]
6. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.
Rühle A; Wiedenmann N; Fennell JT; Mix M; Ruf J; Stoian R; Thomsen AR; Vaupel P; Baltas D; Grosu AL; Nicolay NH
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1650-1660. PubMed ID: 34773163
[TBL] [Abstract][Full Text] [Related]
8. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.
Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Rücker G; Weber WA; Meyer PT; Werner M; Grosu AL; Kayser G
Acta Oncol; 2016 Nov; 55(11):1299-1304. PubMed ID: 27593107
[TBL] [Abstract][Full Text] [Related]
9. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
10. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Zschaeck S; Löck S; Hofheinz F; Zips D; Saksø Mortensen L; Zöphel K; Troost EGC; Boeke S; Saksø M; Mönnich D; Seidlitz A; Johansen J; Skripcak T; Gregoire V; Overgaard J; Baumann M; Krause M
Radiother Oncol; 2020 Aug; 149():189-196. PubMed ID: 32417350
[TBL] [Abstract][Full Text] [Related]
11. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
12. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
13. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy.
Rühle A; Todorovic J; Spohn SSK; Gkika E; Becker C; Knopf A; Zamboglou C; Sprave T; Werner M; Grosu AL; Kayser G; Nicolay NH
Radiat Oncol; 2022 Nov; 17(1):181. PubMed ID: 36376922
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
Rischin D; Hicks RJ; Fisher R; Binns D; Corry J; Porceddu S; Peters LJ;
J Clin Oncol; 2006 May; 24(13):2098-104. PubMed ID: 16648512
[TBL] [Abstract][Full Text] [Related]
17. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
[TBL] [Abstract][Full Text] [Related]
18. Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer.
Zschaeck S; Zöphel K; Seidlitz A; Zips D; Kotzerke J; Baumann M; Troost EGC; Löck S; Krause M
Radiother Oncol; 2021 Feb; 155():204-211. PubMed ID: 33252044
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
Kappler M; Taubert H; Holzhausen HJ; Reddemann R; Rot S; Becker A; Kuhnt T; Dellas K; Dunst J; Vordermark D; Hänsgen G; Bache M
Strahlenther Onkol; 2008 Aug; 184(8):393-9. PubMed ID: 18956515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
